{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:14:32Z","timestamp":1783635272984,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["1122"],"award-info":[{"award-number":["1122"]}],"id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhepr.2026.101818","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:55:36Z","timestamp":1773215736000},"page":"101818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-2542","authenticated-orcid":false,"given":"Najib","family":"Ben Khaled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4275","authenticated-orcid":false,"given":"Raphael","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie S.","family":"Jochheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-9720","authenticated-orcid":false,"given":"Fabian","family":"Artusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-1953","authenticated-orcid":false,"given":"Ursula","family":"Ehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-8891","authenticated-orcid":false,"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-5152","authenticated-orcid":false,"given":"Simon Johannes","family":"Gairing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Piseddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-4044","authenticated-orcid":false,"given":"Monika","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-3061","authenticated-orcid":false,"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-0974","authenticated-orcid":false,"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3803-733X","authenticated-orcid":false,"given":"Philipp","family":"Heumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Leyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"L\u00fcdde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-6459","authenticated-orcid":false,"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-2682","authenticated-orcid":false,"given":"Jens U.","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico N.","family":"De Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-1456","authenticated-orcid":false,"given":"Florian P.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101818_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101818_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2026.101818_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101818_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101818_bib6","article-title":"Improving hepatocellular carcinoma surveillance in the United Kingdom: challenges and solutions","volume":"43","author":"Qurashi","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jhepr.2026.101818_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2018-318193","article-title":"Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study","volume":"69","author":"De Toni","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101818_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101818_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101818_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101818_bib12","article-title":"Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study","volume":"192","author":"Ben","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101818_bib13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib16","first-page":"221","article-title":"Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Alahmari","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jhepr.2026.101818_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.101818_bib18","first-page":"101","article-title":"Early mortality in atezolizumab\/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity","volume":"7","author":"Piseddu","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101818_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221080298","article-title":"Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience","volume":"14","author":"de Castro","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib20","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.3390\/cancers14235966","article-title":"Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience","volume":"14","author":"Sinner","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101818_bib21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMra003007","article-title":"Gastroesophageal variceal hemorrhage","volume":"345","author":"Sharara","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101818_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"Sogaard","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101818_bib23","article-title":"Atezolizumab\/bevacizumab or lenvatinib in hepatocellular carcinoma: multicenter real-world study with focus on bleeding and thromboembolic events","volume":"6","author":"Ben","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101818_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.jhepr.2026.101818_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","article-title":"Prospective validation of the Barcelona clinic liver cancer staging system","volume":"44","author":"Cillo","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101818_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhepr.2026.101818_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting Oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib29","first-page":"e157","volume":"61","author":"Gross","year":"2023"},{"key":"10.1016\/j.jhepr.2026.101818_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000520095","article-title":"Advances in pharmacotherapy of hepatocellular carcinoma: a state-of-the-art review","volume":"40","author":"Reiter","year":"2022","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhepr.2026.101818_bib31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101818_bib32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101818_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e13882","article-title":"Comparing the bleeding risk in hepatocellular carcinoma patients treated with atezolizumab\/bevacizumab versus durvalumab plus tremelimumab","volume":"43","author":"Bhinder","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib34","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101818_bib35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib36","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/apt.70090","article-title":"Therapeutic sequences of systemic therapy after atezolizumab plus bevacizumab for hepatocellular carcinoma: real-world analysis of the IMMUreal cohort","volume":"61","author":"Ben","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101818_bib37","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","article-title":"Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study","volume":"149","author":"Roessler","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101818_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.021","article-title":"Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients","volume":"189","author":"Persano","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101818_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519868","article-title":"Evolution of survival impact of molecular target agents in patients with advanced hepatocellular carcinoma","volume":"11","author":"Kobayashi","year":"2022","journal-title":"Liver Cancer"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:24:20Z","timestamp":1783632260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589555926000893"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101818","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101818"}}